New scan could spot returning prostate cancer at Ultra-Low PSA levels

NCT ID NCT06862856

Recruiting now Diagnosis Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a special PET scan using flotufolastat F 18 can detect prostate cancer that has come back after surgery, even when PSA levels are very low (0.20 ng/mL or less). Researchers will scan 50 men with a history of prostate cancer and a rising PSA after prostate removal. The goal is to see how often the scan finds cancer that standard tests might miss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Flotufolastat F 18 injection (radioactive tracer for PET scan)
What this could lead to: If successful, this could enable earlier and more accurate detection of prostate cancer recurrence, potentially guiding timely treatment decisions.
What could go wrong: This is a small, early-phase study with only 50 participants, so results may not apply to all patients. The scan may also miss some cancers or show false positives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER (ADENOCARCINOMA) PROSTATE SPECIFIC ANTIGEN

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.